Literature DB >> 11805335

Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer.

Shaun P Scott1, Regina Bendix, Philip Chen, Raymond Clark, Thilo Dork, Martin F Lavin.   

Abstract

The human genetic disorder ataxia-telangiectasia (A-T) is characterized by hypersensitivity to ionizing radiation and an elevated risk of malignancy. Epidemiological data support an increased risk for breast and other cancers in A-T heterozygotes. However, screening breast cancer cases for truncating mutations in the ATM (A-T mutated) gene has failed largely to reveal an increased incidence in these patients. It has been hypothesized that ATM missense mutations are implicated in breast cancer, and there is some evidence to support this. The presence of a large variety of rare missense variants in addition to common polymorphisms in ATM makes it difficult to establish such a relationship by association studies. To investigate the functional significance of these changes we have introduced missense substitutions, identified in either A-T or breast cancer patients, into ATM cDNA before establishing stable cell lines to determine their effect on ATM function. Pathogenic missense mutations and neutral missense variants were distinguished initially by their capacity to correct the radiosensitive phenotype in A-T cells. Furthermore missense mutations abolished the radiation-induced kinase activity of ATM in normal control cells, caused chromosome instability, and reduced cell viability in irradiated control cells, whereas neutral variants failed to do so. Mutant ATM was expressed at the same level as endogenous protein, and interference with normal ATM function seemed to be by multimerization. This approach represents a means of identifying genuine ATM mutations and addressing the significance of missense changes in the ATM gene in a variety of cancers including breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805335      PMCID: PMC117407          DOI: 10.1073/pnas.012329699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.

Authors:  G C Smith; R B Cary; N D Lakin; B C Hann; S H Teo; D J Chen; S P Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

Authors:  Y Wang; D Cortez; P Yazdi; N Neff; S J Elledge; J Qin
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

3.  Public health burden of cancer in ataxia-telangiectasia heterozygotes.

Authors:  M Swift
Journal:  J Natl Cancer Inst       Date:  2001-01-17       Impact factor: 13.506

4.  Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries.

Authors:  J H Olsen; J M Hahnemann; A L Børresen-Dale; K Brøndum-Nielsen; L Hammarström; R Kleinerman; H Kääriäinen; T Lönnqvist; R Sankila; N Seersholm; S Tretli; J Yuen; J D Boice; M Tucker
Journal:  J Natl Cancer Inst       Date:  2001-01-17       Impact factor: 13.506

5.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Authors:  A Broeks; J H Urbanus; A N Floore; E C Dahler; J G Klijn; E J Rutgers; P Devilee; N S Russell; F E van Leeuwen; L J van 't Veer
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

6.  Mortality rates among carriers of ataxia-telangiectasia mutant alleles.

Authors:  Y Su; M Swift
Journal:  Ann Intern Med       Date:  2000-11-21       Impact factor: 25.391

7.  Role for ATM in DNA damage-induced phosphorylation of BRCA1.

Authors:  M Gatei; S P Scott; I Filippovitch; N Soronika; M F Lavin; B Weber; K K Khanna
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

8.  Substrate specificities and identification of putative substrates of ATM kinase family members.

Authors:  S T Kim; D S Lim; C E Canman; M B Kastan
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

9.  ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.

Authors:  D S Lim; S T Kim; B Xu; R S Maser; J Lin; J H Petrini; M B Kastan
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

10.  Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity.

Authors:  S G Becker-Catania; G Chen; M J Hwang; Z Wang; X Sun; O Sanal; E Bernatowska-Matuszkiewicz; L Chessa; E Y Lee; R A Gatti
Journal:  Mol Genet Metab       Date:  2000-06       Impact factor: 4.797

View more
  38 in total

1.  Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations.

Authors:  Virginie Jacquemin; Guillaume Rieunier; Sandrine Jacob; Dorine Bellanger; Catherine Dubois d'Enghien; Anthony Laugé; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes.

Authors:  Roger A Greenberg; Bijan Sobhian; Shailja Pathania; Sharon B Cantor; Yoshihiro Nakatani; David M Livingston
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

3.  Novel ATM mutation in a German patient presenting as generalized dystonia without classical signs of ataxia-telangiectasia.

Authors:  Christoph Kuhm; Constanze Gallenmüller; Thilo Dörk; Moritz Menzel; Saskia Biskup; Thomas Klopstock
Journal:  J Neurol       Date:  2015-01-09       Impact factor: 4.849

4.  A single synonymous mutation determines the phosphorylation and stability of the nascent protein.

Authors:  Konstantinos Karakostis; Sivakumar Vadivel Gnanasundram; Ignacio López; Aikaterini Thermou; Lixiao Wang; Karin Nylander; Vanesa Olivares-Illana; Robin Fåhraeus
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

5.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Authors:  Gerard Lozanski; Amy S Ruppert; Nyla A Heerema; Arletta Lozanski; David M Lucas; Amber Gordon; John G Gribben; Vicki A Morrison; Kanti M Rai; Guido Marcucci; Richard A Larson; John C Byrd
Journal:  Leuk Lymphoma       Date:  2012-06-02

6.  Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Authors:  Alisa M Goldstein; Yanzi Xiao; Joshua Sampson; Bin Zhu; Melissa Rotunno; Hunter Bennett; Yixuan Wen; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Meredith Yeager; Belynda Hicks; Jiali Han; Immaculata De Vivo; Stella Koutros; Gabriella Andreotti; Laura Beane-Freeman; Mark Purdue; Neal D Freedman; Stephen J Chanock; Margaret A Tucker; Xiaohong R Yang
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

7.  The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.

Authors:  Denise L Stredrick; Montserrat Garcia-Closas; Marbin A Pineda; Parveen Bhatti; Bruce H Alexander; Michele M Doody; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen J Chanock; Jeffery P Struewing; Alice J Sigurdson
Journal:  Hum Mutat       Date:  2006-06       Impact factor: 4.878

8.  ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs.

Authors:  Denis A Smirnov; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

9.  Low levels of ATM in breast cancer patients with clinical radiosensitivity.

Authors:  Zhiming Fang; Sergei Kozlov; Michael J McKay; Rick Woods; Geoff Birrell; Carl N Sprung; Dédée F Murrell; Kiran Wangoo; Linda Teng; John H Kearsley; Martin F Lavin; Peter H Graham; Raymond A Clarke
Journal:  Genome Integr       Date:  2010-06-24

10.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

Authors:  Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2009-09-24       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.